Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC).

Literature DB >> 32084996

Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC).

M Geissler¹, A Tannapfel², A Reinacher-Schick³, U Martens⁴, J Ricke⁵, J Riera-Knorrenschield⁶, S Kanzler⁷, S Held⁸, V Heinemann⁹, T Seufferlein¹⁰, D Modest¹¹.

Abstract

Year: 2019 PMID： 32084996 DOI： 10.1093/annonc/mdz156.029

Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976

Keyword Cloud
Cited

× No keyword cloud information.

1 in total

1. Characteristics of BRAF ^V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.

Authors: Christelle de la Fouchardière; Romain Cohen; David Malka; Rosine Guimbaud; Héloïse Bourien; Astrid Lièvre; Wulfran Cacheux; Pascal Artru; Eric François; Marine Gilabert; Emmanuelle Samalin-Scalzi; Aziz Zaanan; Vincent Hautefeuille; Benoit Rousseau; Hélène Senellart; Romain Coriat; Ronan Flippot; Françoise Desseigne; Audrey Lardy-Cleaud; David Tougeron
Journal: Oncologist Date: 2019-05-31

1 in total

Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC).

1. Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.

1. Characteristics of BRAF ^V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.